Inflammatix snags $32 mln Series C

Burlingame, California-based Inflammatix, a molecular diagnostics company, has secured $32 million in Series C financing.

10 January 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles